Overview
Alpha-linolenic acid (ALA) is a polyunsaturated omega-3 fatty acid. It is a component of many common vegetable oils and is important to human nutrition.
Indication
For nutritional supplementation and for treating dietary shortage or imbalance.
Associated Conditions
No associated conditions information available.
Research Report
Alpha-Linolenic Acid (DB00132): A Comprehensive Scientific Review
I. Introduction to Alpha-Linolenic Acid (ALA)
Alpha-linolenic acid (ALA) is an 18-carbon polyunsaturated fatty acid (PUFA) belonging to the omega-3 (n-3) family.[1] It holds the distinction of being an essential fatty acid (EFA) for humans and other mammals, meaning it is indispensable for normal physiological function but cannot be synthesized de novo within the body.[3] Consequently, ALA must be obtained entirely from dietary sources. This inherent biological limitation underscores ALA's critical nutritional status and necessitates its inclusion in dietary recommendations to prevent deficiency and support overall health.
ALA serves as the parent compound for the entire omega-3 fatty acid series. While it can be metabolically converted into longer-chain, more unsaturated omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), this conversion process is notably limited in humans.[2] Nevertheless, ALA itself, along with its metabolites, plays significant roles in human nutrition and physiology.[1] It is a structural component of cell membranes and is involved in various signaling pathways.
Found predominantly in plant-based foods, ALA is abundant in certain vegetable oils (flaxseed, canola, soybean), nuts (walnuts), and seeds (flax, chia, hemp).[1] Its presence in common dietary components makes it the most prevalent omega-3 fatty acid in many Western diets.[17] Chemically, ALA is identified by the Chemical Abstracts Service (CAS) number 463-40-1 and the DrugBank identifier DB00132.[1] Its molecular formula is C18H30O2.[1] This report provides a comprehensive overview of the chemical properties, metabolism, dietary sources, physiological functions, health effects, safety considerations, and dietary recommendations pertaining to alpha-linolenic acid.
II. Chemical Properties and Structure
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2021/08/25 | Phase 2 | Recruiting | |||
2020/01/09 | Phase 4 | Completed | Merete Haedersdal | ||
2019/08/05 | Phase 1 | Completed | |||
2019/07/15 | Phase 1 | Completed | |||
2018/08/22 | Phase 4 | Recruiting | Shanghai Dermatology Hospital | ||
2017/02/28 | Not Applicable | Active, not recruiting | |||
2017/01/18 | Phase 3 | Withdrawn | |||
2016/06/14 | Phase 2 | Completed | |||
2016/06/14 | Phase 3 | Completed | |||
2016/06/14 | Phase 3 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| FLAXSEED OIL CAPSULES | general nutrition canada inc. | 02185792 | Capsule - Oral | 594 MG | 5/27/1998 |
| HUILE D'ONAGRE VITAMIN E | le naturiste j.m.b. inc. | 00658332 | Capsule - Oral | 11 % | 12/31/1987 |
| BIO-EFA BORAGE GLA 90 CAP | pge canada (86) inc. | 00756385 | Capsule - Oral | 1 MG / CAP | 12/31/1989 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.
